Jak2 inhibitors: Rationale and role as therapeutic agents in hematologic malignancies

Current Oncology Reports

Volumn 11, Issue 2, 2009, Pages 117-124

  Sayyah, Jacqueline ^b   Sayeski, Peter P ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; ATIPRIMOD; C 7; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; ERLOTINIB; IMATINIB; INCB 18424; JANUS KINASE 2 INHIBITOR; LESTAURTINIB; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; TG 101209; TG 101348; TKIP; UNCLASSIFIED DRUG; WP 1066; Z 3;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG TARGETING; ENZYME ACTIVITY; GENE DELETION; GENE MUTATION; GENETIC ASSOCIATION; HEMATOLOGIC MALIGNANCY; HUMAN; MUTATIONAL ANALYSIS; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; REVIEW;

ANIMALS; HEMATOLOGIC NEOPLASMS; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; PROTEIN KINASE INHIBITORS;

EID: 60349085080     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0018-2     Document Type: Review

References (50)

1. Harpur AG, Andres AC, Ziemiecki A, et al.: JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene 1992, 7:1347-1353.
2. Feng J, Witthuhn BA, Matsuda T, et al.: Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol 1997, 17:2497-2501.
3. Lacronique V, Boureux A, Valle VD, et al.: A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997, 278:1309-1312.
4. Reiter A, Walz C, Watmore A, et al.: The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005, 65:2662-2667.
5. James C, Ugo V, Le Couedic JP, et al.: A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 2005, 434:1144-1148.
6. Kralovics R, Passamonti F, Buser AS, et al.: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
7. Levine RL, Wadleigh M, Cools J, et al.: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
8. Baxter EJ, Scott LM, Campbell PJ, et al.: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
9. Zhao R, Xing S, Li Z, et al.: Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005, 280: 22788-22792.
10. Levine RL, Belisle C, Wadleigh M, et al.: X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006, 107:4139-4141.
11. Shannon K, Van Etten RA: JAKing up hematopoietic proliferation. Cancer Cell 1995, 7:291-293.
12. Giordanetto F, Kroemer RT: Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Eng 2002, 15:727-737.
13. Saharinen P, Vihinen M, Silvennoinen O: Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 2003, 14:1448-1459.
14. Scott LM, Tong W, Levien RL, et al.: JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007, 356:459-468.
15. Luo H, Hanratty WP, Dearolf CR: An amino acid substitution in the Drosophila hopTum-l Jak kinase causes leukemia-like hematopoietic defects. EMBO J 1995, 14:1412-1420.
16. Peeters P, Raynaud SD, Cools J, et al.: Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997, 90:2535-2540.
17. Lacronique V, Boureux A, Monni R, et al.: Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 2000, 95:2076-2083.
18. Carron C, Cormier F, Janin A, et al.: TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 2000, 95:3891-3899.
19. Miyamoto N, Sugita K, Goi K, et al.: The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome. Leukemia 2001, 15:1758-1768.
20. Joos S, Granzow M, Holtgreve-Gez H, et al.: Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int J Cancer 2003, 103:489-495.
21. Murati A, Gelsi-Boyer V, Adelaide J, et al.: PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia 2005, 19:1692-1696.
22. Griesinger F, Hennig H, Hillmer F, et al.: A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 2005, 44:329-333.
23. Lane SW, Fairbairn DJ, McCarthy C, et al.: Leukaemia cutis in atypical chronic myeloid leukaemia with a t(9;22) (p24;q11.2) leading to BCR-JAK2 fusion. Br J Haematol 2008, 142:503.
24. Mercher T, Wernig G, Moore SA, et al.: JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood 2006, 108:2770-2779.
25. Lee JW, Kim YG, Soung YH, et al.: The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006, 25:1434-1436.
26. Kratz CP, Boll S, Kontny U, et al.: Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 2006, 20:381-383.
27. Malinge S, Ben-Abdelali R, Settegrana C, et al.: Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 2007, 109:2202-2204.
28. Meydan N, Grunberger T, Dadi H, et al.: Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996, 379:645-648.
29. Gu Y, Zuo Y, Aikawa R, et al.: Growth hormone signaling and apoptosis in neonatal rat cardiomyocytes. Mol Cell Biochem 2001, 223:35-46.
30. Flowers LO, Johnson HM, Mujtaba MG, et al.: Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function. J Immunol 2004, 172:7510-7518.
31. Sandberg EM, Ma X, He K, et al.: Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of Jak2 tyrosine kinase autophosphorylation. J Med Chem 2005, 48:2526-2533.
32. Boggon TJ, Li Y, Manley PW, Eck MJ: Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 2005, 106:996-1002.
33. Lucet IS, Fantino E, Styles M, et al.: The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 2006, 107:176-183.
34. Pardanani A, Hood J, Lasho T, et al.: TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007, 21:1658-1668.
35. Wernig G, Kharas MG, Okabe R, et al.: Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008, 13:311-320.
36. Verstovsek S, Kantarjian H, Pardanani A, et al.: INCB18424, an oral, selective Jak2 inhibitor, shows significant clinical activity in a phase I/II study in patients with primary myelofi-brosis and post polycythemia vera/essential thrombocythemia myelofibrosis [abstract 7004]. Presented at the 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 30-June 3, 2008.
37. Verstovsek S, Manshouri T, Quintas-Cardama, et al.: WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res 2008, 14:788-796.
38. Ferrajoli A, Faderl S, Van Q, et al.: WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 2007, 23:11291-11299.
39. Sayyah J, Magis A, Ostrov DA, et al.: Z3, a novel Jak2 tyrosine kinase small molecule inhibitor that suppresses Jak2-mediated pathologic cell growth. Mol Cancer Ther 2008, 7:2308-2318.
40. Pardanani A: JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008, 22:23-30.
41. Wang Y, Serradell N: VX-680/MK-0457. Drugs Fut 2007, 32:144.
42. Hexner EO, Serkikoff C, Jan M, et al.: Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008, 111:5663-5671.
43. Ravandi F, Foran J, Verstovsek S, et al.: A phase I trial of AT9283, a mutlitargeted kinase inhibitor, in patients with refractory hematological malignancies [abstract 904]. Presented at the 49th Annual Meeting of the American Society of Hematology. Atlanta, GA; December 8-11, 2007.
44. Grandage VL, Everington T, Linch DC, Khwaja A: G is a potent inhibitor of the JAK2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br J Haematol 2006, 135:303-316.
45. Li Z, Xu M, Xing S, et al.: Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem 2007, 282:3428-3432.
46. Faderl S, Ferrajoli A, Harris D, et al.: Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk Res 2007, 31:91-95.
47. Manshouri T, Quintas-Cardama A, Nussenzveig RH, et al.: The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci 2008, 99:1265-1273.
48. Smith CA, Fan G: The saga of JAK2 mutations and translocations in hematological disorders: Pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. Hum Pathol 2008, 39:795-810.
49. Steensma DP: JAK2 V617F in Myeloid disorders: molecular diagnostic techniques and their clinical utility: A paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006, 8:397-411.
50. Jones AV, Cross NC, White HE, et al.: Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. Haematologica 2008, 93:1560-1564.